MACROGENICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.1 USD | -3.48% |
|
-11.78% | +67.36% |
| Apr. 10 | North American Morning Briefing : Traders Await -2- | DJ |
| Apr. 09 | TD Cowen Upgrades MacroGenics to Buy From Hold | MT |
Financials (USD)
| Sales 2024 * | 72.55M | Sales 2025 * | 140M | Capitalization | 1.04B |
|---|---|---|---|---|---|
| Net income 2024 * | -169M | Net income 2025 * | -121M | EV / Sales 2024 * | 13.3 x |
| Net cash position 2024 * | 77M | Net cash position 2025 * | - | EV / Sales 2025 * | 7.46 x |
| P/E ratio 2024 * |
-6.42
x | P/E ratio 2025 * |
-8.47
x | Employees | 339 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.41% |
More Fundamentals
* Assessed data
More news
Latest transcript on MacroGenics, Inc.
More recommendations
More press releases
| 1 day | -3.48% | ||
| 1 week | -11.78% | ||
| Current month | +9.38% | ||
| 1 month | +3.21% | ||
| 3 months | +52.61% | ||
| 6 months | +205.50% | ||
| Current year | +67.36% |
1 week
16.00
19.08
1 month
12.8219.54
Current year
9.3321.88
1 year
4.2921.88
3 years
2.1336.48
5 years
2.1336.48
10 years
2.1339.90
| Managers | Title | Age | Since |
|---|---|---|---|
Scott Koenig
FOU | Founder | 71 | 00-08-13 |
James Karrels
DFI | Director of Finance/CFO | 57 | 08-04-30 |
Stephen Eck
CTO | Chief Tech/Sci/R&D Officer | 69 | 20-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Margaret Liu
BRD | Director/Board Member | 66 | 23-01-02 |
David Stump
BRD | Director/Board Member | 74 | 13-09-18 |
Edward Hurwitz
BRD | Director/Board Member | 60 | 04-09-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 0 M€ | 0.00% | - | |
| 0.02% | 0 M€ | 0.00% | - | |
| 0.02% | 509 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-17 | 16.1 | -3.48% | 952,938 |
| 24-04-16 | 16.68 | -1.53% | 628,456 |
| 24-04-15 | 16.94 | -3.42% | 820,491 |
| 24-04-12 | 17.54 | -5.24% | 875,221 |
| 24-04-11 | 18.51 | +1.42% | 1,160,279 |
Delayed Quote Nasdaq, April 17, 2024 at 04:00 pm EDT
More quotes
MacroGenics, Inc. is a biopharmaceutical company focused on developing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. It generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is vobramitamab duocarmazine (vobra duo), an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Its clinical pipeline includes two product candidates based on its, bispecific DART technology that co-engages both PD-1 and other checkpoint molecules. These candidates include lorigerlimab and tebotelimab. In addition, it is developing MGD024, a bispecific DART molecule. It is also developing various other programs.
Calendar
2024-04-30
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
16.68
USD
Average target price
24.78
USD
Spread / Average Target
+48.55%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +67.36% | 1.04B | |
| -3.39% | 102B | |
| +2.61% | 96.09B | |
| -1.02% | 22.05B | |
| -18.14% | 20.81B | |
| -6.87% | 19.06B | |
| -40.70% | 16.05B | |
| -26.89% | 14.01B | |
| +1.12% | 13.38B | |
| +22.25% | 11.01B |
- Stock Market
- Equities
- MGNX Stock
